Within this context, it is pertinent to mention that Asians also tend to have varied efficacy responses to some diabetes medications, with more significant glycemic lowering effects with acarbose, glucagon-like peptide-1 (GLP-1) receptor agonists, and Dipeptidyl peptidase-IV (DPP-IV) inhibitors compared to other ethnicities [35, 36]. This evidence concerns the gene DPP4 and diabetes mellitus.